Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis

Completed

Conditions studied: Prostate Cancer

In brief

This is a cross sectional study to examine the relationship between serum calcium and PTHrP and serum PSA in men referred for prostate biopsy at Wake Forest University.

Key facts

Study ID

NCT02397629

Run by

Wake Forest University Health Sciences

People needed

62

Starts

2013-05-01

Expected to finish

2016-05-01

Last updated by the study team

2022-03-11

Who can join

Age: 40 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men age > 40 years
• Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
• Ability and willingness to sign a written, IRB-approved informed consent document

You may not qualify if…

• Men using drugs known to interfere with serum PSA or with serum PTHrP and calcium. Drugs known to interfere with PSA include 5-alpha-reductase inhibitors (Proscar). Drugs known to interfere with calcium and/or PTH include lithium and thiazide diuretics.
• Patients with prior transurethral resection of the prostate (TURP) or equivalent procedure (laser incision). In these men the reduction in prostatic volume may give a biased estimate of the relationship between PSA, calcium and PTHrP.
• Patients on dialysis. These are excluded because dialysis increases the percentage of free PSA in serum.

Where it is running

• Comprehensive Cancer Center of Wake Forset University — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.